Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Epigenetic Regulation01:37

Epigenetic Regulation

4.0K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
4.0K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

49
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
49

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CD19 chimeric antigen receptor T-cell efficacy and toxicity in adults with Richter's transformation and response to bridging therapy.

British journal of haematology·2026
Same author

Glofitamab and epcoritamab for large B cell lymphoma: a real-world retrospective UK analysis of efficacy, tolerability, and impact of treatment sequencing.

Haematologica·2026
Same author

CAR-T therapy for relapsed/refractory large B-cell lymphoma in people living with HIV: efficacy, toxicity and treatment considerations.

Haematologica·2026
Same author

Early PET response predicts the risk of relapse after 2L axi-cel in large B-cell lymphoma.

Blood advances·2026
Same author

Case Report: CAR-T therapy for relapsed diffuse large B-cell lymphoma in a patient with pre-existing Parkinson's disease-unfolding clinical challenges.

Frontiers in oncology·2026
Same author

Bridging practices prior to brexucabtagene autoleucel for mantle cell lymphoma in the United Kingdom: An analysis of modality, response, toxicity and survival.

British journal of haematology·2026

Related Experiment Video

Updated: Feb 24, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

12.4K

Beyond genomics - Targeting the epigenome in diffuse large B-cell lymphoma.

Andrea Kühnl1, David Cunningham1, Ian Chau1

  • 1Department of Medicine, The Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdom.

Cancer Treatment Reviews
|August 20, 2017
PubMed
Summary

Cancer epigenetics, particularly epigenetic deregulation in diffuse large B-cell lymphoma (DLBCL), is a rapidly advancing field. Understanding epigenetic alterations is key for developing targeted therapies and precision medicine approaches in DLBCL.

Keywords:
Diffuse large B cell lymphomaEpigenetic therapiesEpigenome

More Related Videos

Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation
11:06

Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation

Published on: September 20, 2017

6.6K
An Integrated Platform for Genome-wide Mapping of Chromatin States Using High-throughput ChIP-sequencing in Tumor Tissues
10:41

An Integrated Platform for Genome-wide Mapping of Chromatin States Using High-throughput ChIP-sequencing in Tumor Tissues

Published on: April 5, 2018

10.9K

Related Experiment Videos

Last Updated: Feb 24, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

12.4K
Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation
11:06

Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation

Published on: September 20, 2017

6.6K
An Integrated Platform for Genome-wide Mapping of Chromatin States Using High-throughput ChIP-sequencing in Tumor Tissues
10:41

An Integrated Platform for Genome-wide Mapping of Chromatin States Using High-throughput ChIP-sequencing in Tumor Tissues

Published on: April 5, 2018

10.9K

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Genetic alterations in cancer have been extensively studied, leading to targeted therapies.
  • The field of cancer epigenetics is gaining recognition for its role in disease development.
  • Epigenetic deregulation is increasingly implicated in various cancers, including diffuse large B-cell lymphoma (DLBCL).

Purpose of the Study:

  • To review the significant epigenetic changes observed in DLBCL.
  • To explore the potential of targeting epigenetic alterations for precision medicine in DLBCL.
  • To highlight the need for further research into the biological consequences of epigenetic modifications and therapeutic restoration.

Main Methods:

  • Literature review of epigenetic alterations in DLBCL.
  • Analysis of studies on epigenetically-driven DLBCL subgroups.
  • Examination of research on novel epigenetic drugs and their clinical potential.

Main Results:

  • Frequent mutations in epigenome-modifying genes are found in DLBCL.
  • Distinct epigenetically-driven DLBCL subgroups have been identified.
  • Development of novel epigenetic drugs for DLBCL is progressing rapidly.

Conclusions:

  • Epigenetic deregulation plays a crucial role in DLBCL pathogenesis.
  • Targeting epigenetic alterations offers promising avenues for precision medicine in DLBCL.
  • Further research is essential to translate epigenetic therapies into clinical practice for DLBCL patients.